iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Piramal Pharma Reports Strong Revenue Growth in Q4 2023

25 May 2023 , 01:12 PM

Piramal Pharma, the prominent drugmaker, witnessed a significant surge in its stock value. This is an effect as investors celebrated the company’s robust earnings recovery in the quarter ending March 31, 2023.

Strong Financial Performance in Q4 2023:

  • Piramal Pharma reported its highest margin and revenue in FY23 during the fourth quarter, showcasing a remarkable recovery.
  • After incurring a net loss of Rs 90 crore in Q3, the drugmaker rebounded with a net profit of Rs 50 crore in the reviewed quarter.
  • Sequentially, the revenue witnessed a growth of 26 %, reaching Rs 2,164 crore from Rs 1,716 crore in the previous quarter.

Margin Expansion:

  • Piramal Pharma demonstrated a significant improvement in its EBITDA (earnings before interest, taxes, depreciation, and amortization) margin.
  • The margin expanded from 10 % in Q3 to 17 % in Q4, reflecting enhanced operational efficiency and cost management.

Market Performance:

  • On 25-05-2023 at noon, Piramal Pharma was trading with gains of 9.40 % (approximately) at Rs 81 on the NSE, indicating a positive market response to its strong financial results.

For feedback and suggestions, write to us at editorial@iifl.com

Related Tags

  • Buzzing Stocks
  • NSE
  • Pharma
  • Piramal Pharma
  • stocks to watch
  • Top gainers
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.